source
- Oak Hill Bio to go public via SPAC merger, securing $175 million for Angelman syndrome programOak Hill Bio announced it will become a publicly traded company through a merger with the special purpose acquisition company Research Alliance Corporation III. The transaction will provide $75 mi…
- ProMIS Neurosciences early trial shows low brain bleeding and no swelling, hinting at safer Alzheimer’s drugProMIS Neurosciences reported interim safety data from a early‑stage trial of its amyloid‑targeting therapy for Alzheimer’s disease. The analysis pooled data from participants receiving the investi…